Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region

Gene Therapy

Volumn 3, Issue 3, 1996, Pages 235-245

  Caputo, A ^a   Grossi, M P ^a   Bozzini, R ^a   Rossi, C ^a   Betti, M ^a   Marconi, P C ^a   Barbanti Brodano, G ^a   Balboni, P G ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Gene therapy; HIV 1; Tat transdominant mutants

Indexed keywords

CYSTEINE; MUTANT PROTEIN; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; VIRUS LATENCY; VIRUS MUTANT; VIRUS REACTIVATION; VIRUS REPLICATION;

BASE SEQUENCE; CELL LINE; CYSTEINE; GENES, DOMINANT; GENES, TAT; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; OLIGODEOXYRIBONUCLEOTIDES; TRANS-ACTIVATION (GENETICS); VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0029935710     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993; 262: 1011-1018.
2. Folks TM et al. Biological and biochemical characterization of a cloned Leu-3 cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med 1986; 164: 280-284.
3. Frankel AD, Pabo CO Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-1193.
4. Gendelman HE et al. Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci USA 1986; 83: 9759-9763.
5. Helland DE, Welles JL, Caputo A, Haseltine WA. Transcellular transactivation by the human immunodeficiency virus type 1 tat protein. J Virol 1991; 65: 4547-4549.
6. Cullen BR. An introduction to human retroviruses. In: Cullen BR (ed). Human Retroviruses. Oxford University Press: New York, 1993, pp 1-15.
7. Pomerantz RJ, Trono D, Feinberg MB, Baltimore D. Cells non-productively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 1990; 61, 1271-1276.
8. Schwartz S et al. Cloning and functional analysis of multiply spliced mRNA species of HIV-1. J Virol 1990; 64: 2519-2529.
9. Chowdhury M et al. Regulation of the human neurotropic virus promoter by JCV-T antigen and HIV-1 Tat protein. Oncogene 1990; 5: 1737-1742.
10. Kim YS, Risser R. TAR-independent transactivation of the murine cytomegalovirus major immediate-early promoter by the tat protein. J Virol 1993; 67: 239-245.
11. Tomesello ML, Buonaguro FM, Beth-Giraldo E, Giraldo G. Human immunodeficiency virus type 1 tat gene enhances human papillomavirus early gene expression. Intervirology 1993; 36: 57-64.
12. Buonaguro L et al. Effects of the tat protein on the expression of inflammatory cycokines J Virol 1992; 66: 7159-7167.
13. Ensoli B et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 tat protein on cell growth and viral transcription. J Virol 1993; 67: 277-287.
14. Sastry KJ et al. HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell line. J Biol Chem 1990; 265: 20091-20093.
15. Scala G et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 tat protein. J Exp Med 1994; 179: 961-971.
16. Zauli G et al. Tat protein stimulates production of transforming growth factor-β1 by marrow macrophages: a potential mechanism for HIV-1 induced hematopoietic suppression. Blood 1992; 12: 3036-3043.
17. Zauli G et al. Human immunodeficiency virus type 1 tat protein protects lymphoid, epithelial and neuronal cell lines from death by apoptosis. Cancer Res 1993; 53: 4481-4485.
18. Peterlin M et al. Tat trans-activator. In: Cullen BR (ed). Human Retroviruses. Oxford University Press: New York, 1993, pp 75-100.
19. Rice AP, Carlotti F Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 tat protein. J Virol 1990; 64: 1864-1868.
20. Caputo A, Sodroski JG, Haseltine WA. Constitutive expression of HIV-1 tat protein in human Jurkat T cells using a BK virus vector. J Acquir Imm Defic Syndr 1990; 3: 372-379.
21. Lenz J, Haseltine WA. Localization of the leukemogenic determinants of SL3-3, an ecotropic, XC-positive murine leukemia virus of AKR mouse origin. J Virol 1983; 47: 317-328.
22. Horvat RT, Wood C, Balachandran N. Transactivation of human immunodeficiency virus promoter by human herpesvirus-6. J Virol 1989; 63: 970-973.
23. Lusso P et al. Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature 1989; 337: 370-373.
24. Di Luca D et al. Reciprocal in vitro interactions between human herpesvirus-6 and HIV-1 tat AIDS 1991; 5: 1095-1098.
25. Balboni PG et al. Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant. J Med Virol 1993; 41: 289-295.
26. Simmonds P et al. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 1990; 64: 864-872.
27. Harper ME, Marselle LM, Gallo RC, Wong-Staal F. Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci USA 1986; 83: 772-776.
28. Battaglia PA et al. Genetic tests to reveal tat homodimer formation and select tat homodimer inhibitor. Biochem Biophys Res Commun 1994; 201: 701-708.
29. Bahner I et al. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J Virol 1993; 67: 3199-3207.
30. Liem SE, Ramezani A, Li X, Joshi S. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Hum Gene Ther 1993; 4: 625-634.
31. Modesti N et al. Trans-dominant tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol 1991; 3: 759-768.
32. Pearson L et al. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA 1990; 87: 5079-5083.
33. Yu M, Poechla E, Wong-Staal F. Progress towards gene therapy for HIV infection. Gene Therapy 1994; 1: 13-26.
34. Matsukura M et al. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci USA 1987; 84: 7706-7710.
35. Goodchild J et al. Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1988; 85: 5507-5551.
36. Rhodes A, James W. Inhibition of heterologous strains of HIV antisense RNA. AIDS 1991; 5: 145-151.
37. Rittner K, Sczakiel G. Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1. Nucleic Adds Res 1991, 19: 1421-1426.
38. Sczakiel G, Pawlita M. Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J Virol 1991; 65: 468-472.
39. Gyotoku J-I, El-Farrash MA, Fujimoto S. Inhibition of human immunodeficiency virus replication in a human T cell line by antisense RNA expressed in the cell. Virus Genes 1991; 5: 189-202.
40. Joshi S et al. Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression. J Virol 1991; 65: 5524-5530.
41. Lo KMS et al. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 1992; 190: 176-183.
42. Graham GJ, Majo JJ. RNA transcripts of the human immunodeficiency virus trans-activation response element can inhibit action of the viral trans-activator. Proc Natl Acad Sci USA 1990; 87: 5817-5821.
43. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990; 63: 601-608.
44. Lisziewicz J, Rappaport J, Dhar R. Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. New Biol 1991; 3: 82-88.
45. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 1991; 65: 6811-6816.
46. Lisziewicz J et al. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric tat activation response RNA decoy as a strategy for gene therapy of AIDS. Proc Natl Acad Sci USA 1993; 90: 8000-8004.
47. Donaldson YK et al. In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop. J Virol 1994; 68: 5991-6005.
48. Albini A et al. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA 1995; 92: 4838-4842.
49. Lori F et al Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 tat and gag. Gene Therapy 1994; 1: 27-31.
50. Grossi MP et al. New BK virus episomal vector for complementary DNA expression in human cells. Arch Virol 1988; 102: 275-283.
51. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques 1989; 7: 980-990.
52. Plumb M, Stein J, Stein G. Coordinate regulation of multiple histone mRNAs during the cell cycle in HeLa cells. Nucleic Acids Res 1983; 11: 2391-2409.
53. Davis LG, Dibner MD, Battey JF. Basic Methods in Molecular Biology. Elsevier Science Publishing: New York, 1986.
54. Ou C-Y et al. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 1988; 239: 295-297.